medical biotechnology News
-
Centerline Biomedical selected as a 2020 TechConnect Defense Innovation Awardee
The annual TechConnect Defense Innovation Awards recognizes the top 15% of submitted Challenge technologies as ranked by the Selection Committee. To see the full list of awardees, visit https://events.techconnect.org/DTCFall/awards.html Centerline Biomedical will be featured during the “Biotech/Medical II: Innovation Spotlights” session in the upcoming Virtual Defense TechConnect ...
-
ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs
ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time ...
-
dBMEDx™ , Inc. Closes Round of Funding, Selected for Venture Showcase
dBMEDx™ , Inc., a privately-held, wireless medical device company, announces the closing of a capital raise of $1.3 million through the sale of common stock, the company’s third successful capital raise. In addition, the company announces that it has been selected to present at the Colorado BioScience Association’s 2014 BioWest Venture Showcase on September 10. The proceeds ...
By dBMEDx
-
IMBDx to Attend Bio Health Worldwide Online 2020
IMB Dx is attending the ‘Bio Health Worldwide Online 2020’ exhibit sponsored by KOTRA and the South Korean Ministry of Trade, Industry and Energy which will be held for 12 days beginning October 19th, 2020. Over 500 companies in the fields of biotechnology, pharmaceutical, medical device, healthcare, dietary supplements, and protective supplies, as well as over 1,000 potential buyers ...
By IMB Dx, Inc.
-
ELIAS Animal Health Announces First Patient Enrolled in Clinical Trial for ECI™ for the Treatment of Canine B-Cell Lymphoma
ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™), as a treatment for B-cell lymphoma in dogs. The majority of canine lymphomas are derived from B cells. While lymphoma is one of the most responsive ...
-
NeoTherma Oncology Grows Engineering Leadership Team - WICHITA, Kansas
NeoTherma Oncology (NTO) announces they have expanded their leadership team with key senior staff who will advance the development and commercialization of the VectRx System. NTO’s new additions include: Ken Belt, Chief Engineer: Ken will lead RF design, and has 48 years of experience in the medical device field with extensive experience in MRI coil and phased array engineering. ...
-
ELIAS Animal Health Adds Clinical Trial Site for ECI for the Treatment of Canine Osteosarcoma
ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newlydiagnosed appendicular osteosarcoma in dogs. The objective of this clinical trial is to determine whether ECI™ used in ...
-
Newster Weidun at China International Import Expo 2021
Newster Weidun participated at the fourth edition of China International Import Expo (CIIE), one of the most important Chinese import-themed professional trade fairs dedicated to the import of products and services of foreign exhibitors, held from November 5 to 10 at the National Exhibition and Convention Centre in Shanghai. The exhibition, organized by the Ministry of Commerce of the ...
-
Orion Completes Lead Optimization of its CCR2-Targeted Molecule in Only 6 Months!
Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced the successful completion of its OB-004 lead optimization. OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor. The CCL2/CCR2 pathway plays an ...
-
Orion presented the Results of our Successful Phase 1 Clinical Trial at the HIV Research for Prevention Conference
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that they will be presenting the results of their Phase 1 study of OB-002H at the HIVR4P virtual meeting (https://www.hivr4p.org/). The OB-002H-101 Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and ...
-
Therapeutic Developed using Novel Approach to Drug Discovery has Successfully Completed Phase 1 Clinical Trial
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1 study of OB-002H which is an investigational candidate microbicide for HIV prevention. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H ...
-
Daxor Announces Prospective Randomized Control Trial at Duke University Medical Center to Guide Volume Treatment in Heart Failure Patients
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of a prospective randomized control trial (RTC) utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology to guide volume treatment in heart failure patients. Duke University ...
-
Fungal Contamination of Pharmaceutical Products Leads to 33 Eye Infections
Health authorities reported that a tainted dye and injection used during eye surgeries caused 33 cases of rare fungal eye infections. The products were made by the same Florida pharmacy, Franck’s Compounding Lab, that produced the supplements responsible for killing 21 elite polo horses in 2009. All patients with the infections had undergone either eye surgeries or injections. According ...
-
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that it is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP), to support the development of Orion’s lead compound, OB-002, a promising treatment for ...
-
Tainted Medical Wipes Lawsuit Settled by Parents of Dead Toddler
The parents of Harrison Kothari, a two-year old who died from a bacterial infection caused by contaminated medical wipes, have settled a lawsuit with the Wisconsin companies that made and distributed them. The wipes, manufactured by H&P Industries, Inc. and sold by the Triad Group, were recalled in February 2011 after they were found to be contaminated by the rare bacterium Bacillus cereus. ...
-
Marijn Dekkers to Join BioQ Pharma’s Board of Directors
BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that Dr. Marijn Dekkers has agreed to join the Company’s board of directors. Dr. Dekkers is founder and chairman of Novalis LifeSciences, an investment and advisory firm for the life science industry. He served as CEO of Bayer AG, a global life sciences company, from 2010 to 2016 and ...
By BioQ Pharma
-
BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.
BioVentrix, Inc., a privately held medical device company focused on less invasive therapies to treat the left ventricle (LV), known to be the root cause of congestive heart failure (CHF), today announced that it has acquired MateraCor, Inc., a company focused on preventing progression of, and reversing, heart failure through the use of injectable alginate-based hydrogel. “This is an ...
-
Steven G. Felsher and Philip B. Sheibley Appointed to Board of Directors of Modular Medical, Inc.
Modular Medical, Inc. (the "Company" or "Modular Medical") (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced the expansion of its Board of Directors with the appointment of two independent directors, ...
-
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company’s chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors. Mr. Cohen has over 40 years’ experience leading and guiding a variety of private ...
-
Vericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corporate Development and Strategy
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy, effective today. Mr. Fowler joins Vericel with over 15 years of business development, strategy and commercial operations experience in the biotech and medical technology ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you